FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Supplemental Application (SpecGx LLC)

View source ↗

Summary

The FDA approved a supplemental application for lisdexamfetamine dimesylate (generic) submitted by SpecGx LLC under ANDA 211840.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Binge Eating Disorder

Drugs mentioned

• LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

SUPPL AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)